Drug Kickback Ruling Will Make FCA Liability Harder To Prove
By Sean O’Connell, Alison Schurick and Emily Kesler · February 28, 2025, 6:01 PM EST
In U.S. v. Regeneron Pharmaceuticals Inc., decided by the U.S. Court of Appeals for the First Circuit on Feb. 18, the government alleged that the company violated the Anti-Kickback Statute by covering patient...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login